

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Biological relevance of Cytomegalovirus genetic variability in congenitally and postnatally infected children. [*Dell'Oste V, *Landolfo S, co-corresponding authors]

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1680051> since 2019-02-21T12:34:00Z

Published version:

DOI:10.1016/j.jcv.2018.09.019

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1 **Biological relevance of Cytomegalovirus genetic variability in congenitally and**
2 **postnatally infected children**

3

4 Ganna Galitska^a, Matteo Biolatti^a, Marco De Andrea^{a,b}, Agata Leone^c, Alessandra Coscia^c,
5 Luigi Bertolotti^d, Ugo Ala^e, Enrico Bertino^c, Valentina Dell'Oste^{a*}, and Santo Landolfo^{a*}.

6

7 ^a Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy

8 ^b Department of Translational Medicine, Novara Medical School, Novara, Italy

9 ^c Neonatal Unit, Department of Public Health and Pediatric Sciences, University of Turin,
10 Turin, Italy

11 ^d Department of Veterinary Science, University of Turin, Grugliasco, Italy

12 ^e Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin,
13 Italy

14

15 *Corresponding authors at: Laboratory of Viral Pathogenesis, Department of Public Health and
16 Pediatric Sciences, University of Turin, Via Santena 9, 10126, Turin, Italy

17 *E-mail address:* santo.landolfo@unito.it (S. Landolfo); valentina.delloste@unito.it (V.
18 Dell'Oste)

19

20 **Running Head: HCMV genetic variability**

21

22 Word count Abstract: 218

23 Word Count Text: 2740

24

25

26 **ABSTRACT**

27 *Background.* Human cytomegalovirus (HCMV) is the leading cause of congenital infections
28 resulting in severe morbidity and mortality among infected children. Although the virus is
29 highly polymorphic, particularly in genes contributing to immune evasion, the mechanisms
30 underlying its genetic variability and pathogenicity are only partially understood.

31 *Objectives.* We aimed to characterize different HCMV clinical strains isolated from 21
32 congenitally- or postnatally-infected children for *in vitro* growth properties and genetic
33 polymorphisms.

34 *Study design.* The growth of various HCMV isolates was analyzed in different cell culture
35 models. Genetic polymorphism was assessed by genetic and phylogenetic analysis of viral
36 genes involved in virulence (UL144, US28, and UL18), latency (UL133-138), or drug
37 resistance (UL54 and UL97).

38 *Results.* Here, we report a high degree of genetic and phenotypic diversity in distinct HCMV
39 clinical isolates, as shown by their *in vitro* growth properties. In particular, HCMV isolates
40 displayed the highest degree of genetic variability in the UL144 gene, where we were able to
41 define four distinct genotypes within the cohort based on UL144 heterogeneity. Lastly, among
42 all isolates we were able to identify 36 mutations in UL54 and 2 in UL97.

43 *Conclusions.* Our findings indicate that surprisingly high levels of genetic HCMV variability
44 correlate with a high degree of phenotypic polymorphism, which in turn might differentially
45 influence the growth, fitness, and drug susceptibility of HCMV.

46

47 **Keywords:** human cytomegalovirus (HCMV), congenital infection, clinical isolates, genetic
48 variability, viral phenotypes.

49

50

51 **HIGHLIGHTS**

- 52 • HCMV clinical isolates possess different *in vitro* replication properties
- 53 • They all share the same cell tropism, albeit showing different morphological patterns
- 54 • For the most variable gene, UL144, four distinct genotypes were defined
- 55 • In each HCMV isolate, we identified 36 mutations in UL54 and only 2 in UL97

56

57 **1. Background**

58 Human cytomegalovirus (HCMV), a double stranded DNA herpesvirus, is the most
59 frequent cause of congenital malformations worldwide, resulting in neurodevelopmental delay,
60 foetal or neonatal death, and most frequently sensorineural hearing loss [1–3]. It is
61 characterized by a large genome encoding a wide range of gene products, endowed of effective
62 immunomodulatory activity [4–6]. For instance, different viral genes encoding tumor necrosis
63 factor-alpha (TNF- α) receptor (UL144), α -chemokines (UL146-147), β -chemokine receptor
64 (US28) are potential virulence factors associated with severe congenital HCMV infection [7,8].

65 Mounting evidence suggests that HCMV can be highly polymorphic, among and within
66 hosts [9–13], with a high level of intrahost variability comparable to that of RNA viruses. It
67 has been demonstrated that new mutations occur every time that the virus infects a new host,
68 thereby giving rise to a unique viral strain for each infected individual. HCMV infection
69 triggers indeed a selection event where a new genotype becomes dominant due to the selective
70 pressure of the immune response [10]. Another possible explanation of this gap comes from
71 the observation that both viral and host factors can contribute to the onset of HCMV genome
72 mutations, thus fostering virus genetic drift during infection [14,15].

73 HCMV genetic variability, an emerging issue in drug resistance, represents another
74 major obstacle on the way to predicting clinical outcomes of HCMV congenital infections.
75 Currently, the only antiviral therapy available relies on nucleoside analogs, such as ganciclovir
76 (GCV) and valganciclovir (VAL-GCV) [3,16]. In this regard, evidence from adult transplanted
77 patients has shown that DNA polymerase (UL54) and viral phosphotransferase (UL97), two
78 highly polymorphic HCMV genes, seem to play a role in drug resistance against GCV [17].
79 However, further research is clearly needed to fill the lack of information on congenitally
80 HCMV infected children.

81 **2. Objectives**

82 Against this background, the aim of our study was to characterize the *in vitro* phenotype
83 and the degree of genetic polymorphism of HCMV virions freshly isolated from congenitally
84 or postnatally infected children, focusing on genes encoding potential virulence factors, such
85 as UL144, US28, UL18, or contributing to viral latency, such as UL133-138. In addition to the
86 aforementioned immunomodulatory genes, we also analyzed UL97 and UL54 to assess the
87 emergence of drug resistant strains within the enrolled group of patients. Finally, we
88 investigated a potential association between genotype and viral fitness.

89 **3. Study design**

90 *3.1. Patients and samples*

91 Twenty-one children diagnosed with congenital or postnatal HCMV infection were
92 recruited at the Neonatal Unit of the University of Turin from 2015 to 2017. Infection diagnosis
93 was based on RT-PCR HCMV DNA detection in patients' urine and blood samples. Urine
94 samples were collected during the admission medical examination. The Neonatal Unit created
95 a detailed database on clinical and pathological characteristics of recruited patients (indicated
96 as P), summarized in Table 1. All patients were evaluated for neurobehavioral development,
97 growth parameters, cerebral ultrasound, sight and hearing, antiviral and supportive therapy
98 [18]. In addition, they were subjected to a follow up of one year of clinical and neurobehavioral
99 tests for asymptomatic patients, and two years for symptomatic patients along with 6 years of
100 audiology tests.

101 *3.2. Cells and viruses*

102 Primary human foreskin fibroblasts (HFF, American Type Culture Collection, ATCC
103 SCRC-1041™), human retinal pigment epithelial cells (ARPE-19, ATCC CRL-2302™), and

104 human umbilical vein endothelial cells (HUVEC) were cultured as previously described [19].
105 For HFF infection with HCMV clinical isolates, urine samples were primarily inoculated in
106 HFF in order to boost the infected cell population. The isolates were then propagated until
107 approximately 60% of cells demonstrated a cytopathic effect. All isolates were used before
108 passage 3 in order to avoid cell culture adaptation [20,21].

109 *3.3. Viral replication analysis*

110 The replication of cell-associated isolates was quantified by focus expansion assay
111 (FEA), as previously described [22]. Plaque area was calculated using ImageJ software.
112 Statistical analysis was performed using GraphPad Prism version 5.00 for Windows.

113 *3.4. Immunofluorescence microscopy*

114 Indirect immunofluorescence analysis was performed at 72h pi as previously described
115 [23]. The following primary antibodies were used: rabbit polyclonal anti-human von
116 Willebrand factor (vWF) (Sigma-Aldrich), anti-IEA (immediate early antigen; produced in
117 Santo Landolfo's laboratory, University of Turin [24]), mouse monoclonal anti-IEA, UL44
118 (Virusys Corporation), and pan cytokeratin (Sigma-Aldrich). Signals were detected using goat
119 anti-rabbit or goat anti-mouse conjugated secondary antibodies (Life Technologies). Images
120 were taken with a 40× objective by fluorescence microscope Olympus IX-70, equipped with
121 cellSens Standard - Microscopy Imaging Software (Olympus), and ImageJ software was used
122 for image processing.

123 *3.5. DNA sequencing*

124 Genomic DNA was extracted from infected cells by heating the cell with lysis buffer
125 (1.25 M NaCl, 62 mM Tris-Cl pH 8.0, 9 mM EDTA pH 8.0, 0.5% SDS) for 15 min, followed
126 by ammonium acetate/chloroform treatment, and the target genes were amplified using Q5

127 High-Fidelity DNA Polymerase (New England BioLabs). Primers designed on human
128 herpesvirus 5 strain Merlin sequence (NC_006273.2) and PCR conditions are listed in Table
129 2. The amplified products were purified and used for Sanger sequencing (Eurofins Genomics).

130 3.6. Phylogenetic analysis

131 Nucleotide sequences were multiple-aligned to match homologue regions along Merlin
132 reference genome (NC_006273) or along the most similar reference genomes. The alignment
133 was performed using Clustal W, included into Geneious software 9.1, and each gene
134 evolutionary model was selected using jModelTest 2.1.7 [25]. Gene sequences were
135 concatenated, and the phylogenetic tree was reconstructed using a Bayesian approach
136 (MrBayes 3.2.5) [26]. The tree was visualized with FigTree 1.4.2 software (Tree Figure
137 Drawing Tool Version 1.4.2 2006-2014, University of Edinburgh). Robustness of the internal
138 nodes was reported as a posterior probability calculated on the consensus of all the equally
139 probable topologies obtained by the heuristic search. Recombination events were evaluated by
140 using DualBrother plugin in Geneious software [27], SpliTree [28] and SimPlot [29],
141 considering both single genes and concatenated alignments. Association between concatenated
142 tree topology and clinical parameters was investigated using BaTS algorithms evaluating
143 Association Index (AI), Parsimony score (PS) and monophyletic clade (MC) size statistics.

144 3.7 Identification of mutations associated with antiviral drug susceptibility in HCMV clinical 145 strains

146 To ascertain whether the *in vitro* growth variability of HCMV clinical isolates
147 correlated with different degrees of drug susceptibility, we used the web-based search tool
148 mutation resistance analyzer (MRA) is a platform linking identified HCMV drug resistance
149 mutations to specific phenotypes ([http://www.informatik.uni-
150 ulm.de/ni/mitarbeiter/HKestler/hcmv](http://www.informatik.uni-ulm.de/ni/mitarbeiter/HKestler/hcmv)) [30]. Detected mutations are then run through a


151 regularly updated database containing previously published UL97 and UL54 mutations and the
152 corresponding *in vitro* drug susceptibility phenotypes.

153 **4. Results**

154 *4.1. Phenotypic characterization of HCMV clinical strains*

155 First, we carried out phenotypic characterization of HCMV isolates from all patients
156 (P), with the exception of P13 and P19, in HFF. Interestingly, we observed a remarkable
157 variation of fibroblast growth properties among the various isolates, with a high value range of
158 infected foci per well (Table 3).

159 Since cell-free virus transmission is typified by a comet tail phenotype, while cell-
160 associated transmission is characterized by plaques with well-defined edges [22], we sought to
161 determine the transmission pattern of different HCMV clinical isolates by defining plaque
162 morphology. Furthermore, to quantify HCMV replication, we calculated the relative plaque
163 area in HCMV infected HFF. We found that among all isolates, P14 and P15 were those
164 displaying the most aggressive/fast-replicative behavior (Fig. 1A upper panel). These results
165 were also supported by virus plaque morphology analysis showing that P14 displayed larger
166 and comet shaped plaques compared to P9 (Fig. 1A, lower panel). We observed the same
167 infection pattern in HUVEC and ARPE-19 (Fig. 1B and C). Accordingly, in these two cell
168 lines, plaque morphology and area analysis revealed a great heterogeneity (Figure 1B, C) even
169 though the extent of viral growth in HFF did not exactly mirror that seen in HUVEC and ARPE-
170 19. Indeed, in HUVEC P12 and P18 showed a statistically significant larger plaque area
171 compared to that of P9, albeit to a lower extent with respect to P14 and P15, indicating that
172 HCMV replication not only depends on its genetic background, but also on cell environment.




173

174 **Fig. 1. Replication properties of HCMV clinical isolates.** Viral replication was analyzed by focus
 175 expansion assay (FEA). Serial dilutions of HFF (A), HUVEC (B), and ARPE-19 (C) infected by clinical
 176 isolates were cocultured with an excess of uninfected HFF for 5 days. Monolayers were then fixed, and
 177 infected cells were traced by antibodies against HCMV immediate early antigen (IEA), followed by
 178 immunoperoxidase assay. Infectious foci were defined as clusters of at least three infected cells, starting
 179 from single late-stage infected cells. *Upper panel.* Plaque areas were calculated using ImageJ software.
 180 The red bars represent mean values. Differences were considered statistically significant for *, $P < 0.05$;
 181 **, $P < 0.01$; ***, $P < 0.001$ (one-way ANOVA followed by Bonferroni's post-tests, GraphPad Prism
 182 version 5.00 for Windows, for comparison of all isolates *versus* P9). *Lower panel.* Representative
 183 infectious foci of clinical isolates 9 (P9) and 14 (P14) are shown.

184 4.2. Definition of the endothelio- and epithelio-tropic phenotype of different HCMV isolates

185 Next, we assessed HCMV isolates for viral growth. The FEA in HUVEC and ARPE-
 186 19 revealed that all isolates retained their endothelial and epithelial tropism (Fig. 1 B, C). To
 187 rule out the possibility that inoculated infected HFF could overgrow to form infected foci
 188 within HUVEC and ARPE-19, we performed an immunofluorescence double staining for von

189 Willebrand factor (vWF) and pan cytokeratin (Fig. 2 A and B). Based on HCMV
190 aggressiveness, epithelial cell infection resulted in two distinct morphological phenotypes (Fig.
191 2). Whereas fast-replicative isolates, such as P14, formed enlarged flower-shaped syncytial
192 foci, slow-replicative isolates, such as P9, were only visible as single mononucleated infected
193 cells (Fig. 2A). These dual phenotypes were not observed in HUVEC, suggesting a distinct
194 replication pattern among different cell lines and viral isolates (Fig. 2B).



195

196 **Fig. 2. Definition of the endothelio- and epithelio-tropic phenotype of different HCMV clinical**
197 **isolates.** ARPE-19 (A) and HUVEC (B) were cocultured with an excess of HFF infected with
198 representative HCMV clinical isolates (P9 and P14) or mock infected. Cells were fixed 72 h later for
199 immunofluorescence analysis to detect HCMV immediate early antigen IEA (red) and the inherent cell
200 markers: endothelial vWF (green) or epithelial keratin (green). Cell nuclei were counterstained with

201 4',6-diamidino-2-phenylindole (DAPI) (blue). Images were taken with a 40× objective by fluorescence
202 microscopy. The most representative infectious foci are shown.

203 4.3. Genetic characterization of HCMV clinical strains

204 To determine whether phenotypic changes were accompanied by alterations at the DNA
205 level, we performed comparative analysis of a set of genes encoding potential virulence factors
206 (i.e. UL144, US28, UL18), or contributing to viral latency (i.e. UL133-138), or associated with
207 drug resistance (i.e. UL54, UL97) (Table 2). For each region/gene, the sequences were aligned
208 and, based on the best GTR+ Γ evolutionary models, the Bayesian trees were drawn (Fig. S1-
209 S6). Given that HCMV often shows recombination events [31], the alignment was used to
210 create a split network (Fig. 3A), and a set of reference sequences was included. Statistically
211 significant evidence of recombination was identified along the concatenated alignment (Φ p <
212 0.05) (Fig. 3A). Moreover, the SimPlot showed a great heterogeneity (Fig. 3B), reaching the
213 highest variability within the UL144 gene (Fig. 3C), found exclusively in clinical HCMV
214 strains.


215 Remarkably, UL144 amino acid sequence alignment from all HCMV isolates defined
216 four prevalent subgenotypes, namely A, B, C, and A/B (Fig. 4B). The majority of sequences
217 matched with genotype B, whereas those from the isolates P1, P12, and P20, closely related to
218 the Merlin reference strain, were classified under genotype A. Furthermore, sequences derived
219 from the P5, P18 and P21 isolates matched with genotype C, whereas only the P3-derived
220 amino acid sequence was listed under genotype A/B. Interestingly, we noticed that both the
221 P14 and P15 fast-replicative strains belonged to genotype B, indicating that the viral genetic
222 background can indeed determine viral fitness.

223 Noteworthy, considering both nucleotide (Fig. 3C) and amino acid sequences (Fig. 4A),
224 the most important finding deriving from the SimPlot is that the 5' region is the key to

225 discriminate the four genotypes. However, despite having a different genotype, we observed
 226 that almost all cysteines were conserved along the alignment, suggesting that distinct HCMV
 227 isolates may share a similar viral protein folding.

228 Finally, no statistically significant associations were found between the concatenated
 229 tree topology and any clinical parameter reported in Table 1, considering both global (AI and
 230 PS) and local (MCs) association parameters.

231 GenBank accession numbers of all sequences are reported in Table S1.




232

233 **Fig. 3. Genetic analyses on HCMV clinical isolates.** (A) Split network; (B) SimPlot of concatenated
 234 alignment; (C) SimPlot of UL144 alignment; mean nucleotide diversity among samples = 86.59%
 235 (range 73.0% - 100.0%). For both the SimPlots, Merlin strain was used as reference sequence.

A

		1	10	20	30	40	50	60	
Towne	FJ616285	MKPLVMLLLSVLLACIGKTEICKPEEVQLGNQCCPPCKQGRVVTGCCTQTSTCTCLCPNGT							
P9								
P13								
P6								
P7								
P10								
P14								
P17								
HAN32	KJ361954							
CZ.1.2013	KP745691							
P15								
P8								
JER3230	KR534203							
UKNEQAS2	KT634296							
P16								
Davis	JX512198							
P4								
P11								
CZ.2.2012	KP745643							
P2								
PAV24	KJ361968							
P3								
BE.14.2010	KP745721							
P1								
Merlin	KU221090							
Merlin	NC006273							
U11	GU179290							
BE.17.2010	KP745727							
P5								
P12								
P21								
P18								
		64	70	80	90	100	110	120	125
Towne	FJ616285	YVSGLYNCNCTECNDEVTIRNCTSTNNTVCASKNNTSFSIPGVQHHQR-QMHTARVTVKQ							
P9								
P13								
P6								
P7								
P10								
P14								
P17								
HAN32	KJ361954							
CZ.1.2013	KP745691							
P15								
P8								
JER3230	KR534203							
UKNEQAS2	KT634296							
P16								
Davis	JX512198							
P4								
P11								
CZ.2.2012	KP745643							
P2								
PAV24	KJ361968							
P3								
BE.14.2010	KP745721							
P1								
Merlin	KU221090							
Merlin	NC006273							
U11	GU179290							
BE.17.2010	KP745727							
P5								
P12								
P21								
P18								

B


236

237 **Fig. 4. UL144 gene analysis.** Amino acid alignment (A) and neighbor joining tree (B), based on amino
 238 acidic sequence alignment, are reported. Dots indicate identical residue. Genotypes are indicated for
 239 each tree clade.

240 4.4. Antiviral drug susceptibility of HCMV clinical strains

241 Complete sequences of UL54 and UL97 from HCMV isolates were uploaded in MRA
 242 and compared to the wild-type sequence of the drug-sensitive HCMV strain TB40-BAC4
 243 [32,33]. MRA identified 36 mutations in the UL54 gene associated with genetic polymorphism
 244 previously published [34–39], whereas only two mutations were detected in UL97, probably
 245 due to a major gene stability (Figure 5A and B) [35,40–43].

246 Interestingly, drug resistance-associated mutations varied among patients, especially in
 247 UL54 and to a lesser extent in UL97 (Figure 5A and B).



248
 249 **Fig. 5. Antiviral susceptibility testing.** The heterogeneity of UL54 (A) and UL97 (B) genes is reported.
 250 *Left panel.* The heat maps show the presence and the positions of amino acidic changes, and the
 251 histograms show the frequency of each modification. *Right panel.* The Bayesian tree describes the
 252 genetic relationship among samples based on nucleotide alignment.

253 **5. Discussion**

254 The clinical and biological relevance of HCMV genetic variability in congenitally and
255 postnatally infected children has been the focus of intense research over the past few years. In
256 this study, we sought to determine whether and to what extent the differences in gene
257 composition affected viral fitness. For this purpose, we enrolled 21 pediatric patients with
258 confirmed congenital or postnatal HCMV infection. We evaluated the degree of genetic
259 polymorphism of HCMV clinical strains by genetic and phylogenetic analyses, primarily
260 focusing on viral genes involved in virulence, latency, and drug resistance. In parallel, we ran
261 an extensive *in vitro* analysis of all clinical isolates to characterize viral growth properties and
262 viral tropism in fibroblasts, endothelial and epithelial cells. Our results suggest that HCMV
263 clinical isolates possess phenotypic differences as judged by both viral dissemination rate and
264 replication properties, which define the extent of strain aggressiveness. Particularly, the two
265 strains P14 and P15 were the most aggressive and fast-replicative ones because they could give
266 rise to infectious foci characterized by comet-shaped plaques, typically observed in laboratory
267 strains [22]. Altogether, these results support the hypothesis that HCMV heterogeneity may
268 have an impact on viral fitness, influencing both viral dissemination rate and replication
269 properties.

270 The reliability of such results could be inferred from the different cell lines employed
271 for virus propagation and their low passage number (≤ 3) to ensure that no cell-culture
272 adaptation had occurred [20,21]. All clinical isolates in the recruited group of patients were
273 able to infect both epithelial and endothelial cells displaying no difference in their cell tropism,
274 while they displayed a unique morphological pattern in cells infected with fast-replicative
275 isolates. Interestingly, the enlarged flower-shaped syncytial foci typical of epithelial, but not
276 endothelial, cells obtained with the most aggressive strains were similar to those observed by
277 Tandon and coworkers in HFF infected with UL96-deleted Towne bacterial artificial

278 chromosome (Δ UL96BAC) [44], which could be partly ascribed to different maturation
279 patterns between isolates.

280 The analysis of specific HCMV genome regions suggests that genetic variability among
281 HCMV isolates may impact viral fitness. Indeed, here we report enhanced sequence diversity,
282 identified thanks to the 5' region of UL144 alignment used as a discriminatory criterion.
283 Interestingly, the high degree of nucleotide heterogeneity mirrors in the amino acidic sequence,
284 indicating a considerable difference among UL144 genotypes. This is interesting, as UL144 is
285 a potent NF- κ B activator [45] that plays a role in virus-mediated immune evasion [46,47]. This
286 high heterogeneity of UL144 strongly influenced the split tree configuration based on the
287 concatenated alignment, highlighting the role of this gene in the description of genetic
288 relationships between CMV isolates. The same sample clustering has been demonstrated for
289 both UL54 and UL97 genes, known to be involved in antiviral drug resistance. In both cases,
290 the similarity among samples was high even though a number of previously reported mutations
291 were identified in UL54 and to a lower extent in UL97. However, all treated patients so far
292 responded to valganciclovir therapy. Nonetheless, we are not able to fully exclude the
293 possibility that the reported mutations might have an impact on the antiviral therapy over a
294 prolonged time.

295 It is highly likely that multiple strains of CMV are present in each patient of our group
296 of patients, similar to cases being previously extensively reported in the literature [12].
297 However, we used an approach based on the Sanger sequencing of PCR products obtained from
298 cell culture. The sensitivity of this method is strongly dependent on the relative frequency of
299 viral variants. In particular, low-abundance viral populations are likely to be missed and the
300 overall viral diversity to be underestimated. Thus, although sequence electropherograms did
301 not show clear evidence of multiple signals (i.e., double peaks and/or high background signal),
302 we can not exclude the presence of mixed infections. Further investigations can be carried out

303 to evaluate the role of mixed infections in pediatric infected patients, including PCR product
304 cloning strategies or next generation sequencing approaches.

305 The limits of our study include the small number of the recruited patients, the short
306 collection period (two years) in the limited geographic area. Besides, not all the analysis were
307 available for all the samples, f.i. propagation and isolation of the virus failed for P13
308 (simultaneous presence of pathogenic bacteria and yeast in the patient's urine, since patient 13
309 was presented with severe sepsis at admission) and P19 (low viral load in urine sample).

310 In conclusion, our study may suggest that genotypic variability is associated with *in*
311 *vitro* phenotypic diversity in HCMV clinical strains isolated from a group of congenitally and
312 postnatally infected patients. In addition, our results indicate that genetic polymorphisms
313 across the UL54 genome might play a role in multidrug resistance HCMV infection, pointing
314 to UL54 as a potential therapeutic target to consider when treating congenital HCMV disease.
315 This is, to our knowledge, the first detailed analysis that tries to associate in the same cohort of
316 patients' genetic polymorphism and viral fitness. Although the results achieved so far do not
317 allow any definitive conclusion, it emerges that a strong genetic HCMV variability is reflected
318 in a remarkable phenotypic polymorphism that could affect virus growth properties and *in vivo*
319 fitness.

320

321 **Competing interest**

322 None declared.

323 **Authors' contribution**

324 Study design: SL, VDO, MDA; laboratory analyses: GG, VDO, MB; patients'
325 management and clinical data collection: EB, AL, AC; statistical/phylogenetic analyses: LB
326 and UA; manuscript writing: GG, VDO, SL.

327 **Acknowledgements**

328 We sincerely thank Dr. Manuela Sironi for her helpful suggestions and valuable
329 comments on the manuscript and genetic analysis.

330 **Funding**

331 This work was supported by: European Commission under the Horizon2020 program
332 (H2020-MSCA-ITN-2015); Italian Ministry of Education, University and Research-MIUR
333 (PRIN 2015 to MDA, 2015W729WH; PRIN 2015 to VDO, 2015RMNSTA). The funding
334 agencies had no role in study design, data collection and interpretation, as well as in the
335 decision to submit this work for publication.

336 **Ethical approval**

337 This study was approved by the Research Ethics Committee of the University Hospital
338 of Turin “A.O.U. Città della Salute e della Scienza di Torino – A.O. Ordine Mauriziano –
339 A.S.L. TO1” (No 007816). Informed consent was obtained from parents of all study
340 participants prior to the collection of demographic and clinical data, along with biological
341 samples. The work was carried out in accordance with the Declaration of Helsinki.

342 **References**

- 343 [1] P. Griffiths, I. Baraniak, M. Reeves, The pathogenesis of human cytomegalovirus, *J.*
344 *Pathol.* 235 (2015) 288–297. doi:10.1002/path.4437.
- 345 [2] W.J. Britt, Congenital Human Cytomegalovirus Infection and the Enigma of Maternal
346 Immunity, *J. Virol.* 91 (2017) e02392-16. doi:10.1128/JVI.02392-16.

- 347 [3] W.D. Rawlinson, S.B. Boppana, K.B. Fowler, D.W. Kimberlin, T. Lazzarotto, S. Alain,
348 K. Daly, S. Doutré, L. Gibson, M.L. Giles, J. Greenlee, S.T. Hamilton, G.J. Harrison, L.
349 Hui, C.A. Jones, P. Palasanthiran, M.R. Schleiss, A.W. Shand, W.J. van Zuylen,
350 Congenital cytomegalovirus infection in pregnancy and the neonate: consensus
351 recommendations for prevention, diagnosis, and therapy, *Lancet Infect. Dis.* 17 (2017)
352 e177–e188. doi:10.1016/S1473-3099(17)30143-3.
- 353 [4] I. Brizić, L. Hiršl, W.J. Britt, A. Krmpotić, S. Jonjić, Immune responses to congenital
354 cytomegalovirus infection, *Microbes Infect.* (2017) doi: 10.1016/j.micinf.2017.12.010
- 355 [5] G. Rossini, C. Cerboni, A. Santoni, M.P. Landini, S. Landolfo, D. Gatti, G. Gribaudo, S.
356 Varani, Interplay between human cytomegalovirus and intrinsic/innate host responses: a
357 complex bidirectional relationship, *Mediators Inflamm.* (2012) 607276.
358 doi:10.1155/2012/607276.
- 359 [6] S. Landolfo, M. De Andrea, V. Dell’Oste, F. Gugliesi, Intrinsic host restriction factors of
360 human cytomegalovirus replication and mechanisms of viral escape, *World J. Virol.* 5
361 (2016) 87–96. doi:10.5501/wjv.v5.i3.87.
- 362 [7] B.P. McSharry, S. Avdic, B. Slobedman, Human cytomegalovirus encoded homologs of
363 cytokines, chemokines and their receptors: roles in immunomodulation, *Viruses.* 4 (2012)
364 2448–2470. doi:10.3390/v4112448.
- 365 [8] E. Murphy, T. Shenk, Human cytomegalovirus genome, *Curr. Top. Microbiol. Immunol.*
366 325 (2008) 1–19.
- 367 [9] E. Puchhammer-Stöckl, I. Görzer, Human cytomegalovirus: an enormous variety of
368 strains and their possible clinical significance in the human host, *Future Virol.* 6 (2011)
369 259–271. doi:10.2217/fvl.10.87.

- 370 [10] N. Renzette, B. Bhattacharjee, J.D. Jensen, L. Gibson, T.F. Kowalik, Extensive genome-
371 wide variability of human cytomegalovirus in congenitally infected infants, *PLoS Pathog.*
372 7 (2011) e1001344. doi:10.1371/journal.ppat.1001344.
- 373 [11] N. Renzette, L. Gibson, J.D. Jensen, T.F. Kowalik, Human cytomegalovirus intrahost
374 evolution-a new avenue for understanding and controlling herpesvirus infections, *Curr.*
375 *Opin. Virol.* 8 (2014) 109–115. doi:10.1016/j.coviro.2014.08.001.
- 376 [12] N. Renzette, C. Pokalyuk, L. Gibson, B. Bhattacharjee, M.R. Schleiss, K. Hamprecht,
377 A.Y. Yamamoto, M.M. Mussi-Pinhata, W.J. Britt, J.D. Jensen, T.F. Kowalik, Limits and
378 patterns of cytomegalovirus genomic diversity in humans, *Proc. Natl. Acad. Sci. U. S. A.*
379 112 (2015) e4120-4128. doi:10.1073/pnas.1501880112.
- 380 [13] N. Renzette, S.P. Pfeifer, S. Matuszewski, T.F. Kowalik, J.D. Jensen, On the Analysis of
381 Intrahost and Interhost Viral Populations: Human Cytomegalovirus as a Case Study of
382 Pitfalls and Expectations, *J. Virol.* 91 (2017). doi:10.1128/JVI.01976-16.
- 383 [14] N. Vabret, N. Bhardwaj, B.D. Greenbaum, Sequence-Specific Sensing of Nucleic Acids,
384 *Trends Immunol.* 38 (2017) 53–65. doi:10.1016/j.it.2016.10.006.
- 385 [15] M.H. Christensen, S.R. Paludan, Viral evasion of DNA-stimulated innate immune
386 responses, *Cell. Mol. Immunol.* 14 (2017) 4–13. doi:10.1038/cmi.2016.06.
- 387 [16] S.H. James, D.W. Kimberlin, Advances in the prevention and treatment of congenital
388 cytomegalovirus infection, *Curr. Opin. Pediatr.* 28 (2016) 81–85.
389 doi:10.1097/MOP.0000000000000305.
- 390 [17] T.E. Komatsu, A. Pikis, L.K. Naeger, P.R. Harrington, Resistance of human
391 cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative

392 resistance pathways, *Antiviral Res.* 101 (2014) 12–25.
393 doi:10.1016/j.antiviral.2013.10.011.

394 [18] D.W. Kimberlin, P.M. Jester, P.J. Sánchez, A. Ahmed, R. Arav-Boger, M.G. Michaels,
395 N. Ashouri, J.A. Englund, B. Estrada, R.F. Jacobs, J.R. Romero, S.K. Sood, M.S.
396 Whitworth, M.J. Abzug, M.T. Caserta, S. Fowler, J. Lujan-Zilbermann, G.A. Storch, R.L.
397 DeBiasi, J.-Y. Han, A. Palmer, L.B. Weiner, J.A. Bocchini, P.H. Dennehy, A. Finn, P.D.
398 Griffiths, S. Luck, K. Gutierrez, N. Halasa, J. Homans, A.L. Shane, M. Sharland, K.
399 Simonsen, J.A. Vanchiere, C.R. Woods, D.L. Sabo, I. Aban, H. Kuo, S.H. James, M.N.
400 Prichard, J. Griffin, D. Giles, E.P. Acosta, R.J. Whitley, National Institute of Allergy and
401 Infectious Diseases Collaborative Antiviral Study Group, Valganciclovir for symptomatic
402 congenital cytomegalovirus disease, *N. Engl. J. Med.* 372 (2015) 933–943.
403 doi:10.1056/NEJMoa1404599.

404 [19] F. Gugliesi, V. Dell’oste, M. De Andrea, R. Baggetta, M. Mondini, C. Zannetti, B.
405 Bussolati, G. Camussi, M. Gariglio, S. Landolfo, Tumor-derived endothelial cells evade
406 apoptotic activity of the interferon-inducible IFI16 gene, *J. Interferon Cytokine Res. Off.*
407 *J. Int. Soc. Interferon Cytokine Res.* 31 (2011) 609–618. doi:10.1089/jir.2011.0001.

408 [20] C. Sinzger, K. Schmidt, J. Knapp, M. Kahl, R. Beck, J. Waldman, H. Hebart, H. Einsele,
409 G. Jahn, Modification of human cytomegalovirus tropism through propagation in vitro is
410 associated with changes in the viral genome, *J. Gen. Virol.* 80 (Pt 11) (1999) 2867–2877.
411 doi:10.1099/0022-1317-80-11-2867.

412 [21] M.N. Prichard, M.E. Penfold, G.M. Duke, R.R. Spaete, G.W. Kemble, A review of
413 genetic differences between limited and extensively passaged human cytomegalovirus
414 strains, *Rev. Med. Virol.* 11 (2001) 191–200. doi: 10.1002/rmv.315

- 415 [22] C. Sinzger, J. Knapp, B. Plachter, K. Schmidt, G. Jahn, Quantification of replication of
416 clinical cytomegalovirus isolates in cultured endothelial cells and fibroblasts by a focus
417 expansion assay, *J. Virol. Methods.* 63 (1997) 103–112.
- 418 [23] V. Dell’Oste, D. Gatti, F. Gugliesi, M. De Andrea, M. Bawadekar, I. Lo Cigno, M.
419 Biolatti, M. Vallino, M. Marschall, M. Gariglio, S. Landolfo, Innate Nuclear Sensor IFI16
420 Translocates into the Cytoplasm during the Early Stage of In Vitro Human
421 Cytomegalovirus Infection and Is Entrapped in the Egressing Virions during the Late
422 Stage, *J Virol.* 88.12 (2014) 6970-82. doi: 10.1128/JVI.00384-14.
- 423 [24] S. Pautasso, G. Galitska, V. Dell’Oste, M. Biolatti, R. Cagliani, D. Forni, M. De Andrea,
424 M. Gariglio, M. Sironi, S. Landolfo, Evasion Strategy of Human Cytomegalovirus to
425 Escape Interferon- β -Induced APOBEC3G Editing Activity, *J. Virol.* (2018).
426 doi:10.1128/JVI.01224-18.
- 427 [25] D. Posada, jModelTest: phylogenetic model averaging, *Mol. Biol. Evol.* 25 (2008) 1253–
428 1256. doi:10.1093/molbev/msn083.
- 429 [26] J.P. Huelsenbeck, F. Ronquist, MRBAYES: Bayesian inference of phylogenetic trees,
430 *Bioinformatics.* 17 (2001) 754–755. doi:10.1093/bioinformatics/17.8.754.
- 431 [27] V.N. Minin, K.S. Dorman, F. Fang, M.A. Suchard, Dual multiple change-point model
432 leads to more accurate recombination detection, *Bioinformatics.* 21 (2005) 3034–3042.
433 doi:10.1093/bioinformatics/bti459.
- 434 [28] D.H. Huson, D. Bryant, Application of phylogenetic networks in evolutionary studies,
435 *Mol. Biol. Evol.* 23 (2006) 254–267. doi:10.1093/molbev/msj030.

- 436 [29] K.S. Lole, R.C. Bollinger, R.S. Paranjape, D. Gadkari, S.S. Kulkarni, N.G. Novak, R.
437 Ingersoll, H.W. Sheppard, S.C. Ray, Full-length human immunodeficiency virus type 1
438 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype
439 recombination, *J. Virol.* 73 (1999) 152–160.
- 440 [30] M. Chevillotte, J. von Einem, B.M. Meier, F.-M. Lin, H.A. Kestler, T. Mertens, A new
441 tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes,
442 *Antiviral Res.* 85 (2010) 318–327. doi:10.1016/j.antiviral.2009.10.004.
- 443 [31] M. Faure-Della Corte, J. Samot, I. Garrigue, N. Magnin, S. Reigadas, L. Couzi, C.
444 Dromer, J.-F. Velly, J. Déchanet-Merville, H.J.A. Fleury, M.-E. Lafon, Variability and
445 recombination of clinical human cytomegalovirus strains from transplantation recipients,
446 *J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol.* 47 (2010) 161–169.
447 doi:10.1016/j.jcv.2009.11.023.
- 448 [32] M. Chevillotte, A. Schubert, T. Mertens, J. von Einem, Fluorescence-based assay for
449 phenotypic characterization of human cytomegalovirus polymerase mutations regarding
450 drug susceptibility and viral replicative fitness, *Antimicrob. Agents Chemother.* 53 (2009)
451 3752–3761. doi:10.1128/AAC.00165-09.
- 452 [33] C. Sinzger, G. Hahn, M. Digel, R. Katona, K.L. Sampaio, M. Messerle, H. Hengel, U.
453 Koszinowski, W. Brune, B. Adler, Cloning and sequencing of a highly productive,
454 endotheliotropic virus strain derived from human cytomegalovirus TB40/E, *J. Gen. Virol.*
455 89 (2008) 359–368. doi:10.1099/vir.0.83286-0.
- 456 [34] S. Chou, N.S. Lurain, A. Weinberg, G.Y. Cai, P.L. Sharma, C.S. Crumpacker, Interstrain
457 variation in the human cytomegalovirus DNA polymerase sequence and its effect on

- 458 genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV
459 Laboratories, *Antimicrob. Agents Chemother.* 43 (1999) 1500–1502.
- 460 [35] S. Chou, L.C. Van Wechel, H.M. Lichy, G.I. Marousek, Phenotyping of cytomegalovirus
461 drug resistance mutations by using recombinant viruses incorporating a reporter gene,
462 *Antimicrob. Agents Chemother.* 49 (2005) 2710–2715. doi:10.1128/AAC.49.7.2710-
463 2715.2005.
- 464 [36] S. Chou, R.J. Ercolani, M.K. Sahoo, M.I. Lefterova, L.M. Strasfeld, B.A. Pinsky,
465 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations
466 by deep sequencing, *Antimicrob. Agents Chemother.* 58 (2014) 4697–4702.
467 doi:10.1128/AAC.03214-14.
- 468 [37] M. Mousavi-Jazi, L. Schloss, B. Wahren, M. Brytting, Point mutations induced by
469 foscarnet (PFA) in the human cytomegalovirus DNA polymerase, *J. Clin. Virol. Off.*
470 *Publ. Pan Am. Soc. Clin. Virol.* 26 (2003) 301–306.
- 471 [38] A. Weinberg, D.A. Jabs, S. Chou, B.K. Martin, N.S. Lurain, M.S. Forman, C.
472 Crumpacker, Cytomegalovirus Retinitis and Viral Resistance Study Group, Adult AIDS
473 Clinical Trials Group Cytomegalovirus Laboratories, Mutations conferring foscarnet
474 resistance in a cohort of patients with acquired immunodeficiency syndrome and
475 cytomegalovirus retinitis, *J. Infect. Dis.* 187 (2003) 777–784. doi:10.1086/368385.
- 476 [39] C. Gilbert, A. Azzi, N. Goyette, S.-X. Lin, G. Boivin, Recombinant phenotyping of
477 cytomegalovirus UL54 mutations that emerged during cell passages in the presence of
478 either ganciclovir or foscarnet, *Antimicrob. Agents Chemother.* 55 (2011) 4019–4027.
479 doi:10.1128/AAC.00334-11.

- 480 [40] O. Ijichi, D. Michel, T. Mertens, K. Miyata, Y. Eizuru, GCV resistance due to the
481 mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a
482 second mutation at D605E, *Antiviral Res.* 53 (2002) 135–142.
- 483 [41] H. Hu, D.A. Jabs, M.S. Forman, B.K. Martin, J.P. Dunn, D.V. Weinberg, J.L. Davis,
484 Cytomegalovirus Retinitis and Viral Resistance Study Group, Comparison of
485 cytomegalovirus (CMV) UL97 gene sequences in the blood and vitreous of patients with
486 acquired immunodeficiency syndrome and CMV retinitis, *J. Infect. Dis.* 185 (2002) 861–
487 867. doi:10.1086/339603.
- 488 [42] A.J. Reddy, A.K. Zaas, K.E. Hanson, S.M. Palmer, A single-center experience with
489 ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and
490 outcome, *J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant.* 26 (2007) 1286–
491 1292. doi:10.1016/j.healun.2007.09.012.
- 492 [43] K. Tanaka, T. Hori, Y. Yoto, N. Hatakeyama, M. Yamamoto, N. Suzuki, H. Tsutsumi,
493 Human cytomegalovirus UL97 D605E polymorphism has a high prevalence in
494 immunocompetent Japanese infants and children, *Microbiol. Immunol.* 55 (2011) 328–
495 330. doi:10.1111/j.1348-0421.2011.00327.x.
- 496 [44] R. Tandon, E.S. Mocarski, Cytomegalovirus pUL96 is critical for the stability of pp150-
497 associated nucleocapsids, *J. Virol.* 85 (2011) 7129–7141. doi:10.1128/JVI.02549-10.
- 498 [45] E. Poole, C.A. King, J.H. Sinclair, A. Alcamí, The UL144 gene product of human
499 cytomegalovirus activates NFκB via a TRAF6-dependent mechanism, *EMBO J.* 25
500 (2006) 4390–4399. doi:10.1038/sj.emboj.7601287.
- 501 [46] C.A. Benedict, K.D. Butrovich, N.S. Lurain, J. Corbeil, I. Rooney, P. Schneider, J.
502 Tschopp, C.F. Ware, Cutting edge: a novel viral TNF receptor superfamily member in

503 virulent strains of human cytomegalovirus, *J. Immunol. Baltim. Md* 1950. 162 (1999)
504 6967–6970.

505 [47] T.H. Watts, J.L. Gommerman, The LIGHT and DARC sides of herpesvirus entry
506 mediator, *Proc. Natl. Acad. Sci. U. S. A.* 102 (2005) 13365–13366.
507 doi:10.1073/pnas.0506707102.

508

509

510 **Tables**511 **Table 1.** Clinical-pathological characteristics of patients

MOTHER								FETUS			
Previous history of childbirths		Infection discovery		Type of infection		Trimester of infection		Fetal anomalies		Viral load (amniotic fluid)	
<i>First born</i>	71 %	<i>0 = unsuspected during pregnancy</i>	50%	<i>1 = first</i>	47.6%	<i>1st</i>	14.3%	19%	<i>Neg</i>	9.5%	
		<i>1 = serology</i>	50%	<i>2 = relapse</i>	14.3%	<i>2nd</i>	33.3%				
<i>Not first born</i>	29 %	<i>2 = ultrasound abnormalities (not IUGR)</i>	0	<i>3 = acquired after birth</i>	9.5%	<i>3rd</i>	19.1%		<i>Pos</i>	0%	
		<i>3 = IUGR</i>	0	<i>N/A^b</i>	28.6%	<i>After birth</i>	9.5%		<i>N/A</i>	90.5 %	
						<i>N/A</i>	23.8%				
CHILDBIRTH				NEWBORN							
Gestational age (mean week): 37.6		Reanimation at birth: 14.3%		Sex		Birth weight (0= \geq 10 ^o pc; 1=3-10 pc; 2= \leq 3 ^o pc)		Head circumference (0= \geq 10 ^o pc/ 1= \leq 10 ^o pc)			
Children age at time of sampling (mean month): 2.5				<i>F</i> 47.6%	<i>M</i> 52.4%	<i>0</i>	61.9%	<i>0</i>	71.5%		
						<i>1</i>	9.5%				
						<i>2</i>	19%	<i>1</i>	19%		
						<i>N/A</i>	9.5%	<i>N/A</i>	9.5%		
INSTRUMENTAL EXAMS ANOMALIES ^c						LABORATORY ANALYSIS ANOMALIES ^f					
Hearing ^c		Cerebral ultrasound ^c		Cerebral MR ^d or CT ^{e,c}		Platelets ^c		Neutrophils ^c		Hepatic functionality ^c	
<i>0</i>	76.2%	<i>0</i>	52.3%	<i>0</i>	38%	<i>0</i>	80.9 %	<i>0</i>	76.2%	<i>0</i>	71.4%
<i>1</i>	14.3%	<i>1</i>	42.9%	<i>1</i>	28.6%	<i>1</i>	4.8%	<i>1</i>	9.5%	<i>1</i>	9.5%
<i>N/A</i>	9.5%	<i>N/A</i>	4.8%	<i>N/A</i>	33.4%	<i>N/A</i>	14.3 %	<i>N/A</i>	14.3%	<i>N/A</i>	19.1%
VIRAL LOAD						ANTIVIRAL THERAPY					
Viral load (urine)				Viral load (blood)				Valganciclovir (os) at time of sampling		Valganciclovir (os) after sampling	
<i>Neg</i>		0%		<i>Neg</i>		4.8%		4.8%		14.3%	
<i>Pos</i>		100%		<i>Pos</i>		66.7%					
<i>N/A</i>		0%		<i>N/A</i>		28.5%					
<i>Mean (PFU/ml)</i>		2364034.9		<i>Mean (PFU/ml)</i>		43318.8					

512

513 ^aIUGR: intrauterine growth restriction; ^bN/A: not available; ^c0: normal, 1: pathologic; ^dMR: magnetic
 514 resonance; ^eCT: computed tomography; ^fabnormal laboratory indicators: platelet count < 100,000/mm³,
 515 neutrophils count < 1,000/mm³, ALAT > 80 IU/l, conjugated bilirubin plasma level > 2 mg/dl and >
 516 10% of total bilirubin, per os: oral administration.

517

518 **Table 2.** Primers and reaction conditions for amplifying full length HCMV ORFs.

Gene	Forward primer (5'-3')	Reverse primer (5'-3')	Annealing T (°C)	Amplicon size (bp)	Nucleotide position
UL144	TCGTATTACAAACC GCGGAGAGGAT	ACTCAGACACG GTTCCGTAA	62	736	182073-182808
UL18	CACACGGCTAAGA GGATACATC	GGTAAAGTAGT GCAGGAACGC	62	1146	23873-25017
US28	ACCGAGGGCAGAA CTGGTGC	TACGAAAAGAC CGAGGTAGCG	62	1145	225411-226525
UL133-138 A	AGAGTATGTCAGT CAAGGGC	GAGTAGATCGA GCAGAGAAT	52	1390	187371-188760
UL133-138 B	CGACACGGAGTTT GAGATTC	GCCCTTGACT GACATACTCT	58	1070	188741-189810
UL133-138 C	TCGGCAGCCGCTG TAGAGAT	GAATCTCAAA CTCCGTGTCTG	62	990	189791-190780
UL54A	ATTCAGATCTCGTG CGTGTGCT	TGTGCCATGAT GATGGAAGG	58	1223	79737-80959
UL54B	TGGTGCGCGATCT GTTCAACAC	GCTTCCGAGAC CTCGGATCCT	58	1399	78891-80289
UL97	GGACATGAGCGAC GAGAGCT	GTACGCGACAC GAGGACATC	58	774	142886-143659

519

520

521 **Table 3.** Growth properties of HCMV clinical isolates.

Patients' code	Mean No. of IEA positive foci/infected cell dilution		
	HFF	HUVEC	ARPE-19
P1	8*10 ²	5*10 ³	4*10 ²
P2	6*10 ²	1*10 ³	5*10 ³
P3	2*10 ²	1*10 ³	7*10 ³
P4	3*10 ²	3*10 ³	2*10 ²
P5	5*10 ²	2*10 ³	3*10 ²
P6	7*10 ²	1*10 ²	7*10 ³
P7	2*10 ²	1*10 ²	3*10 ²
P8	7*10 ²	1*10 ³	1*10 ²
P9	2*10 ²	1*10 ⁵	8*10 ⁴
P10	1*10 ³	1*10 ³	6*10 ³
P11	4*10 ³	3*10 ⁴	3*10 ²
P12	9*10 ³	1.3*10 ⁴	1*10 ¹
P14	3*10 ¹	1*10 ²	1*10 ²
P15	6*10 ²	2*10 ²	3*10 ²
P16	5*10 ²	1*10 ¹	1*10 ²
P17	1.9*10 ⁴	2.2*10 ⁵	4.4*10 ⁵
P18	4*10 ⁴	2.7*10 ⁵	7.9*10 ⁵
P20	4*10 ³	5*10 ³	7*10 ³
P21	9*10 ²	5*10 ²	1*10 ²

522